Results 151 to 160 of about 24,681 (243)

Peer review of the pesticide risk assessment of the active substance cinmethylin. [PDF]

open access: yesEFSA J
European Food Safety Authority (EFSA)   +49 more
europepmc   +1 more source

In Vivo Evaluation of Psoralen in a Copper Sulfate–Induced Chick (Gallus gallus domesticus) Emesis Model and In Silico Analysis of Its Interaction With D2, 5‐HT3A, and Muscarinic Receptors

open access: yesChemistryOpen, Volume 15, Issue 8, August 2026.
Psoralen (PSN) demonstrates significant dose‐dependent antiemetic activity in a copper sulfate–induced chick emesis model. Integrated in vivo and in silico analyses reveal reduced retching frequency, prolonged latency, and favorable multi‐receptor interactions with D2, 5‐HT3A, and muscarinic receptors, highlighting PSN as a promising multi‐target ...
Kishor Chandra   +12 more
wiley   +1 more source

Development of a Disease‐Specific Virtual Malaria Population for Physiologically‐Based Pharmacokinetic Modeling

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 8, August 2026.
ABSTRACT Malaria remains a major global health challenge, with an urgent need for new therapies to combat the evolving resistance to anti‐malarial treatments. Physiologically‐based pharmacokinetic (PBPK) modeling offers a promising approach to accurately predict PK, optimize dosing strategies, reduce development time and cost, and de‐risk the ...
Junjie Ding   +3 more
wiley   +1 more source

Developmentally dynamic chromatin state at loci regulating organ crosstalk by remote sensing and signaling. [PDF]

open access: yesEpigenetics Chromatin
Parmar A   +6 more
europepmc   +1 more source

A Physiologically Based Pharmacokinetic Model to Predict Potential Drug–Drug Interactions of TPN171, a Novel Phosphodiesterase Type 5 Inhibitor

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 8, August 2026.
ABSTRACT TPN171 is a potent phosphodiesterase type 5 inhibitor used to treat pulmonary arterial hypertension and erectile dysfunction, primarily metabolized by CYP3A4. This study aimed to evaluate its drug–drug interaction (DDI) potential and determine the optimal dosing when co‐administered with CYP3A4 modulators.
Guanghui Tian   +8 more
wiley   +1 more source

DDIapp—A Web‐Based Application for Static Drug–Drug Interaction Assessment

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 8, August 2026.
ABSTRACT In this work we describe the development of a web‐based application for static drug–drug interaction (DDI) risk assessment in accordance with the International Council for Harmonization (ICH) M12 guidance. The app was built using the Shiny for Python framework and it employs a modular mathematical modeling structure that incorporates models ...
Hirotaka Watase   +5 more
wiley   +1 more source

Physiologically Based Pharmacokinetic Model of Brigatinib in Healthy Volunteers and Patients With Cancer

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 8, August 2026.
ABSTRACT Brigatinib, an oral ALK inhibitor for metastatic NSCLC, lacks dosing guidance for special populations such as the Chinese. This study developed a physiologically based pharmacokinetic (PBPK) model using European data from patients with hepatic/renal impairment and drug–drug interaction (DDI) studies (itraconazole, rifampin). The model was then
Yichao Xu   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy